1292P Exploratory patient-reported outcomes (PROs) among patients with RET-fusion non-small cell lung cancer (NSCLC) in LIBRETTO-001: A phase I/II trial of selpercatinib
Minchom, A.R., Tan, D.S.W., Massarelli, E., Subbiah, V., Boni, V., Robinson, B., Wirth, L.J., Hess, L.M., Huang, X., Kherani, J.F., Olek, E., McCoach, C.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
1291P Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI)
McCoach, C., Tan, D.S.W., Besse, B., Goto, K., Zhu, V.W., Rolfo, C.D., Farajian, S., Potter, L., Kherani, J.F., Soldatenkova, V., Olek, E., Lee, P., Park, K.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article
1922P Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292)
Wirth, L.J., Robinson, B., Boni, V., Tan, D.S.W., McCoach, C., Massarelli, E., Hess, L.M., Huang, X., Kherani, J.F., Olek, E., Subbiah, V.
Published in Annals of oncology (01.09.2020)
Published in Annals of oncology (01.09.2020)
Get full text
Journal Article